Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Squamous cell carcinoma of lung+6

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BNT327

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drugNo placebo

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bms-986340

Contact Research Centre

Breast neoplasm

Recruiting

Registered drugNo placebo

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Goserelin Acetate

Contact Research Centre

HER2 positive breast cancer

Recruiting

Registered drugNo placebo

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

InvestigationalNo placebo

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:SIGVOTATUG VEDOTIN

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer stage IIIA+2

Recruiting

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Breast cancer+3

Recruiting

Registered drugNo placebo

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drugNo placebo

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Breast cancer+2

Recruiting

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capivasertib

Contact Research Centre

K-ras gene mutation+2

Recruiting

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Budesonide

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you

46 trials match your criteria

Squamous cell carcinoma of lung+6

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Non-small cell lung cancer metastatic

Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)

Breast neoplasm

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

HER2 positive breast cancer

Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

Squamous cell carcinoma of lung+4

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

Squamous cell carcinoma of lung+4

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Non-small cell lung cancer stage IIIA+2

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Breast cancer+3

A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

Non-small cell lung cancer

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Breast cancer+2

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

K-ras gene mutation+2

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Non-small cell lung cancer+1

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.